<DOC>
	<DOCNO>NCT03048461</DOCNO>
	<brief_summary>The purpose study evaluate effect autologous platelet-rich plasma ( PRP ) treatment androgenetic alopecia . This randomized clinical trial evaluate effect autologous platelet rich plasma subject moderate androgenetic alopecia . Approximately 30 subject randomize study . The study design 18-month study consist 2 phase . This study pilot study design determine feasibility procedure . Subjects currently live Chicago metropolitan area meet inclusion/exclusion criterion consider enrollment .</brief_summary>
	<brief_title>The Effect Platelet-rich Plasma Subjects With Androgenetic Alopecia</brief_title>
	<detailed_description />
	<mesh_term>Alopecia</mesh_term>
	<mesh_term>Alopecia Areata</mesh_term>
	<criteria>1 . Males females ≥ 18 year old ≤55 year old 2 . Subjects good health judge investigator . 3 . Diagnosed dermatologist moderate androgenetic alopecia . 4 . Subject seek treatment androgenetic alopecia . 5 . Subject never previously use finasteride minoxidil consistently use finasteride minoxidil least 1 year . 6 . Subjects willing ability understand provide inform consent participation study able communicate investigator . 1 . Other androgenetic alopecia , evidence another skin condition affect treatment area would interfere clinical assessment . 2 . Subjects unwilling avoid initiate treatment minoxidil finasteride duration study ; subject treat minoxidil finasteride least 1 year , unwilling avoid change dose regimen medication duration study . 3 . Willing refrain wash hair use hair product 24 hour treatment visit 4 . History clinically significant hematologic disorder determine investigator . 5 . Subjects currently receive anticoagulant antiplatelet therapy . 6 . Subjects daily Aspirin therapy cardiovascular disease . 7 . Subjects chronic NSAID use , unable wean . 8 . Subject know HIV positive . 9 . History recurrent facial labial herpes simplex infection 10 . History hypertrophic scar keloids 11 . Known genetic disorder affect fibroblast collagen , achondroplasia , osteogenesis imperfecta , etc . 12 . Subjects requirement use local systemic steroid immunosuppressive agent 13 . Pregnant breast feed 14 . Uncooperative patient patient neurological disorder incapable follow direction predictably unwilling return followup examination . 15 . Subjects unable understand protocol give inform consent .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>